Procyte Corp. (NASDAQ:PRCY) announced an agreement withKaken Pharmaceutical Co. Ltd. of Tokyo to develop and marketProcyte's peptide-copper hair growth technology in Asia. Thepeptide compounds are being explored as a potential treatmentfor hair loss prevention and hair growth. Under the terms ofthe agreement, Kaken will have exclusive rights for specificpeptide-copper compounds in Asia, which includes Japan,China, Taiwan, Southeast Asian countries, India and Korea.Procyte will supply preclinical and clinical trial quantities ofthe compounds and Kaken will be responsible for all clinicaldevelopment of the hair growth technology in Asia.
(c) 1997 American Health Consultants. All rights reserved.